Suppr超能文献

知母-黄柏药对通过调控 IRE1α/XBP1s 通路抑制 SREBP-1c 改善小鼠肝脂肪变性。

Zhimu-Huangbai herb-pair ameliorates hepatic steatosis in mice by regulating IRE1α/XBP1s pathway to inhibit SREBP-1c.

机构信息

School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China.

Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China.

出版信息

Phytomedicine. 2024 Nov;134:156017. doi: 10.1016/j.phymed.2024.156017. Epub 2024 Sep 2.

Abstract

BACKGROUND

Currently, there is a lack of validated pharmacological interventions for non-alcoholic fatty liver disease (NAFLD), which is characterized by the accumulation of hepatic triglyceride. Zhimu-Huangbai (ZH) herb-pair is a traditional Chinese medicine that regulates glucose and lipid metabolism disorders. However, the precise mechanisms underlying the preventive effects of hepatic triglyceride induced by high-fat diet (HFD) remain elusive.

PURPOSE

The study aimed to examine the impact of ZH herb-pair on NAFLD in mice and explore the underlying mechanisms, particularly its effects on endoplasmic reticulum (ER) stress and lipid metabolism.

METHODS

NAFLD was induced in mice using HFD, and the treated mice were orally administered ZH, metformin (Glucophage) or lovastatin. The lipid metabolism factors, ER stress markers, and the unfolded protein response (UPR) branch factors were measured using immunohistochemistry, western blotting or qRT-PCR. Co-Immunoprecipitation (CoIP) was performed to reveal the connection between SCAP and SREBP-1c. Tunicamycin (TM) and plasmid delivery were used to induce acute ER stress or crease XBP1 gain function models. The main compounds in ZH binding to IRE1α protein were studied by molecular docking and cellular thermal shift assay (CETSA).

RESULTS

Treatment with ZH significantly ameliorated hepatic steatosis and reduced lipid synthesis process mainly inhibiting the expression of mature active form of SREBP-1c through relieving ER stress. The expression of IRE1α and XBP1s was inhibited after treatment with ZH. In addition, ZH improved the fatty liver phenotype caused by XBP1 overexpression via decreasing srebp1c transcription. In vitro experimental results suggested that the main compounds in ZH decreased cellular TG contents. Mechanistically, ZH targeted IRE1α and inhibited XBP1s mRNA expression to relieve ER stress and inhibit SREBP-1c production.

CONCLUSIONS

ZH herb-pair can protect against NAFLD by reducing the expression of SREBP-1c, in part, via regulating IRE1α/XBP1s pathway.

摘要

背景

目前,非酒精性脂肪性肝病(NAFLD)缺乏有效的药物干预手段,其特征为肝内三酰甘油(TG)堆积。知母-白芍药对是一种调节糖脂代谢紊乱的中药,但知母-白芍药对通过高脂饮食(HFD)诱导肝 TG 产生的预防性作用的确切机制仍不清楚。

目的

本研究旨在观察知母-白芍药对对小鼠 NAFLD 的影响,并探讨其作用机制,特别是其对内质网(ER)应激和脂代谢的影响。

方法

采用 HFD 诱导小鼠 NAFLD,知母-白芍药对、二甲双胍(格华止)和洛伐他汀灌胃治疗。采用免疫组化、Western blot 或 qRT-PCR 检测脂代谢因子、ER 应激标志物和未折叠蛋白反应(UPR)分支因子。采用共免疫沉淀(CoIP)揭示 SREBP-1c 与 SCAP 的联系。采用衣霉素(TM)和质粒转染诱导急性 ER 应激或增加 XBP1 功能获得模型。采用分子对接和细胞热转移分析(CETSA)研究知母-白芍药对与 IRE1α 蛋白结合的主要化合物。

结果

知母-白芍药对治疗可显著改善肝脂肪变性,减少脂质合成过程,主要通过减轻 ER 应激抑制成熟活性形式 SREBP-1c 的表达。知母-白芍药对治疗后 IRE1α 和 XBP1s 的表达受到抑制。此外,知母-白芍药对通过降低 srebp1c 转录改善 XBP1 过表达引起的脂肪肝表型。体外实验结果表明,知母-白芍药对的主要化合物可降低细胞内 TG 含量。知母-白芍药对的作用机制为靶向作用于 IRE1α,抑制 XBP1s mRNA 表达,从而减轻 ER 应激,抑制 SREBP-1c 生成。

结论

知母-白芍药对可通过降低 SREBP-1c 的表达来减轻 NAFLD,部分机制是通过调节 IRE1α/XBP1s 通路。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验